PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial underway
Disease control OngoingThis study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
New drug combo shows promise for recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in about 31 people whose endometrial, ovarian, or related cancers have returned. The main goal is to find the safest dose and understand side effects. Participants must have ce…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial is testing the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. The goal is to see if taking olaparib for two cycles can safely shrink tumors and stop them from growing. Olap…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise in ovarian cancer safety trial
Disease control OngoingThis early-phase study tested adding the experimental drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to find the safest dose and check for side effec…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New hope for Hard-to-Treat ovarian cancer: targeted drug combo under study
Disease control OngoingThis study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study compares two treatments for women with ovarian, fallopian tube, or peritoneal cancer that has come back after initial therapy. One group gets olaparib alone, the other gets olaparib plus tremelimumab. Olaparib blocks cancer cells from repairing themselves, while tremel…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Ovarian cancer drug study aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase study is testing a drug called adavosertib in women with advanced ovarian, fallopian tube, or peritoneal cancer before they have surgery to remove tumors. The goal is to see how the drug changes the DNA of cancer cells, which may help doctors plan more effective …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC